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OBJECTIVE
We examined the association of urine complement proteins with progression
to end-stage renal disease (ESRD) or death in people with type 2 diabetes and
proteinuric diabetic kidney disease (DKD).
RESEARCH DESIGN AND METHODS
Using targeted mass spectrometry, we quantified urinary abundance of 12 com-
plement proteins in a predominantly Mexican American cohort with type 2
diabetes and proteinuric DKD (n = 141). The association of urine complement
proteins with progression to ESRD or death was evaluated using time-to-event
analyses.
RESULTS
At baseline, median estimated glomerular filtration rate (eGFR) was 54 mL/min/
1.73 m2 and urine protein-to-creatinine ratio 2.6 g/g. Sixty-seven participants
developed ESRD or died, of whom 39 progressed to ESRD over a median of 3.1 years
and 40 died over a median 3.6 years. Higher urine CD59, an inhibitor of terminal
complement complex formation, was associated with a lower risk of ESRD (hazard
ratio [HR] [95%CI per doubling] 0.50 [0.29–0.87]) anddeath (HR [95%CI] 0.56 [0.34–
0.93]), after adjustment for demographic and clinical covariates, including baseline
eGFR and proteinuria. Higher urine complement components 4 and 8 were
associated with lower risk of death (HR [95% CI] 0.57 [0.41–0.79] and 0.66
[0.44–0.97], respectively); higher urine factor H–related protein 2, a positive
regulator of the alternative complement pathway, was associated with greater
risk of death (HR [95% CI] 1.61 [1.05–2.48]) in fully adjusted models.
CONCLUSIONS
In a largely Mexican American cohort with type 2 diabetes and proteinuric DKD,
urine abundance of several complement and complement regulatory proteins was
strongly associated with progression to ESRD and death.
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD)
and end-stage renal disease (ESRD) (1). Our diagnostic and therapeutic tools have
not kept pace with the rising incidence of diabetes and DKD (2), significantly
curtailing our ability to diagnose DKD, particularly early in its course, and tomodify
its natural history beyond what is possible under current standards of care. Ethnic
minorities, in particular, bear a large and growing burden of diabetes and DKD (3).
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As such, there is an urgent need to
identify new pathogenic mechanisms
and evaluate the potential of these
mechanisms as diagnostic and therapeu-
tic targets.
Substantial evidence, largely derived
from rodent models, links complement
and complement regulatory proteins to
the DKD pathogenesis (4). Notably, com-
plement activation has been implicated
in mediating the tubulointerstitial injury
by proteinuria in CKD (5). However, a
comprehensive assessment of the role of
the complement cascade in human DKD
has not been conducted to date. Such
an evaluation has been impeded in part
due to absence of methods to quantify
the ensemble of complement proteins
in parallel.
We developed a novel targeted
proteomics method to quantify the
abundance of 12 complement and com-
plement regulatory proteins, which
were detectable in urine, and used
this method to quantify these proteins
in a cohort of predominantly Hispanic
participants with type 2 diabetes and
proteinuric DKD. Urine was selected as
the biofluid of choice because it is readily
and noninvasively available, is already
extensively used in clinical diagnos-
tics, and is of increasing interest for bio-
marker discovery. In addition, mounting
evidence suggests that urine protein
composition is substantially modified
by proteins reabsorbed or elaborated
from the cells lining the nephron (6–9),
suggesting that urine protein composi-
tion may inform on the intrarenal path-
ogenic mechanisms and as such has
prognostic value for disease progression.
In this study, we report the association of
the urine abundance of several comple-
ment proteins with progression to ESRD
and all-cause mortality.
RESEARCH DESIGN AND METHODS
Study Populations
This study used samples from two pop-
ulations: for the discovery analysis using
untargeted proteomics, we used urine
samples and clinical data from a cross-
sectional subset of participants from the
University of Washington (UW) DKD re-
pository. The validation step using tar-
geted proteomics used samples from
the longitudinal Golden State cohort.
For theUWDKD repository, as previously
described (10), clinic patients with type
1 diabetes were recruited from 2011 to
2016. DKD was defined as: 1) an esti-
mated glomerular filtration rate (eGFR)
,60mL/min/1.73m2 and aurine albumin-
to-creatinine ratio (ACR) $30 mg/g or
2) ACR $300 mg/g. Control partici-
pants had$30 years of type 1 diabetes,
eGFR $90 mL/min/1.73 m2, and ACR
,300 mg/g. This study was approved
by the UW Institutional Review Board
(IRB).
The Golden State cohort, a prospec-
tive study of vascular calcification in pa-
tients with type 2 diabetes and DKD, has
also been previously described (11).
From 2004 to 2008, participants with
type 2 diabetes, defined as diabetes
diagnosed at $30 years of age and
treated with diet or oral hypoglycemic
agents for $6 months, were recruited.
DKD was defined as a urine protein-to-
creatinine ratio $0.5 g/g at enrollment
or in the preceding 12 months and one
or more of the following: 1) typical his-
tologic changes on kidney biopsy, 2)
diabetes duration $5 years and diabe-
tic retinopathy, or 3) diabetes duration
$10 years without diabetic retinopathy.
Patients with a kidney transplant or on
dialysis were excluded. All participants
provided written informed consent.
The study was approved by the IRB at
the Los Angeles Biomedical Research
Institute. Links to participant identifica-
tion were destroyed after the last study
contact (2011). Use of de-identified sam-
ples from this study was approved by the
UW IRB.
Covariates
Demographic data and past medical his-
tory were obtained from medical re-
cords and self-report and medications
from pill bottles. Vital signs were average
of duplicate measurements. Hyperten-
sion was defined as systolic blood pres-
sure/diastolic blood pressure (SBP/DBP)
.140/90, use of antihypertensive med-
ications, or a clinical history of hyper-
tension. Hemoglobin A1c (HbA1c) was
measured using high-performance liquid
chromatography (ToshioMedics, Inc., Fos-
ter City, CA). Plasma lipidsweremeasured
using conventional enzymatic methods
with LDL calculated from Friedewald
formula. Serum creatinine, urine albu-
min, and urine creatinine were mea-
sured using the enzymatic reaction (12),
immunoturbidometric assays (13), and
the modified Jaffe´ reaction (14), respec-
tively. eGFR was estimated using the
Modification of Diet in Renal Disease
(MDRD) Study equation (15).
Outcomes
Following the baseline visit, the Golden
State cohort participants were reas-
sessed at 12 and 24 months or within
3 months of the first dialysis treatment,
whichever occurred first. Progression to
ESRD and occurrence of death was ver-
ified by the study staff who contacted
the study participants or next of kin
every 6 months via phone, letters, or
home visits, as well as linkage to the
U.S. Renal Data System (USRDS; through
31 December 2008) and National Death
Index (through 31 December 2007). ESRD
was defined as a requirement for main-
tenance dialysis or kidney transplanta-
tion. The time to ESRD was ascertained
from the last study contact or the date
of the linkage with the USRDS, which-
ever occurred later. Time to death was
ascertained from the last study contact
or the date of the linkage with the
National Death Index or USRDS, which-
ever occurred later.
Urine Sample Collection and
Processing for Proteomic Analysis
Random urine samples were aliquoted
and stored at 280°C. The samples used
for this study had not undergone prior
freeze-thaw and showed no evidence of
volume loss on inspection. A total of 100–
300 mL of stored samples were thawed,
precipitated with 43 volume of ice-cold
1:1 mixture of acidified methanol/
acetone (1 mmol/L HCl in methanol
added to acetone in 1:1 ratio), and in-
cubated overnight at220°C. Precipitated
proteins were reconstituted in 0.2%
RapiGest/100 mmol/L ammonium bi-
carbonate with vigorous mixing over-
night at 4°C. Protein concentration was
measured by Bradford assay (Pierce).
a-Enolase (Aspergillus oryzea) was spiked
into samples (1mg enolase/10mg protein)
as a protein internal standard for digestion
and liquid chromatography–mass spec-
trometry (LC-MS). A total of 10 mg urine
protein per sample was reduced with
dithiothreitol, alkylated with iodoacet-
amide, and digested with two additions
of trypsin (Promega, Madison, WI) at
a 1:20 weight-for-weight ratio for 3 h,
and overnight, at 37°C with mixing. Af-
ter digestion, RapiGest was hydrolyzed
by addition of 1% trifluoroacetic acid
and incubation at 37°C for 45 min.
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Samples were spun (14,000g for 10 min),
and the supernatant was dried down
and stored at 280°C until LC-MS. Be-
fore analysis, samples were reconsti-
tuted with 0.1% formic acid (FA)/5%
acetonitrile.
Untargeted Proteomics
Peptides (0.375 mg) were injected on a
trap column (40 3 0.1 mm, XBridge
BEHC18, 5 mm; Waters, Milford, MA),
desalted for 5 min at a flow of 4 mL/min,
separated on a pulled-tip analytical col-
umn (150 3 0.075 mm, XBridge BEHC18,
3.5 mm; Waters), and heated to 50°C
with a three-segment linear gradient of
acetonitrile, 0.1% FA (B) in water, and
0.1% FA (A) as follows: 0–3 min 1–7% B,
3–53min 7–25% B, 53–60min 25–35%B,
and then 80% B and re-equilibration at
0.4 mL/min (nanoACQUITY UPLC; Waters).
Tandem mass spectrometry (MS/MS)
spectra were acquired on Orbitrap Fu-
sion (Thermo Fisher Scientific, Waltham,
MA) operated in data-dependent
mode with higher-energy collisional dis-
sociation fragmentation (normalized
collisional energy 25%) and MS/MS ac-
quisition. MS spectra were acquired at
resolution 60,000 and MS/MS spectra
(MS/MS selection window 2 Da) at res-
olution 15,000. Peptides and proteins
were identified using the Comet search
engine,withPeptideProphet andProtein-
Prophet validation (20 ppm tolerance
window for precursors and products,
Cys alkylation and methionine oxidation
as fixed and variable modifications,
respectively).
Targeted Proteomics
Proteins of interest were quantified us-
ing parallel reaction–monitoring (PRM)
LC-MS on an Orbitrap Fusion Tribrid
mass spectrometer (Thermo Fisher Sci-
entific) connected to a nanoACQUITY
UPLC (Waters). Peptides were selected
from untargeted proteomics and prior-
itized based on proteotypic properties
using public resources, prediction mod-
els, and the human SRMAtlas (http://
www.srmatlas.org/). Best peptides by
chromatographic data were selected
for PRM LC-MS (Supplementary Table
1). Selected peptides were monitored
by targeting precursor ions in the quad-
rupole analyzer (selection window 2.0
Da) and full-scan MS/MS after higher-
energy collisional dissociation fragmen-
tation (normalized collisional energy
29%) in the Orbitrap analyzer with high
resolution (15,000). Scheduled acquisition
with 5-min acquisition windows was set
up for each peptide precursor using
Skyline (https://skyline.ms/project/home/
software/skyline/begin.view), allowing a
maximum of 20 concurrent PRM experi-
ments. Acquired data were processed in
Skyline, and automated integration was
manually checked. The identity of the
chromatographic peaks was ascertained
by matching the PRM MS/MS spectra to
those from the untargeted dataset (dot
product .0.9 and mass precision ,5
ppm). For quantification, peptides were
selected from those measured in PRM
analyses based on correlation $0.9
(Supplementary Fig. 1). Of the two pep-
tides in the most highly correlated pair,
one was selected for quantification
based on the abundance and the small-
est number of samples with missing or
undetectable peptides (Supplementary
Table 2).
Statistical Methods
Continuous variables were summarized
by mean, SD, median, and interquartile
range (IQR) and categorical variables by
number and percent. Peptide and pro-
tein abundance data (targeted pro-
teomics) were log2-transformed and
converted to z scores. The correlation
between the abundance of each protein
and the eGFR and urine protein was
calculated using the Pearson correlation.
The time to the first occurrence of death
or ESRD was modeled by abundance of
each complement protein and other
variables using Cox proportional hazards
models. Three single-protein models
were fitted per protein. Model 1 included
the abundance of the given protein in
urine and the sample LC-MS batch. For
complement factor H–related protein
2 (FHR2), model 1 also included a second
variable indicating whether the abun-
dance was below the limit of detection.
This variable was added to prevent undue
influence by the individuals with un-
detectable urine FHR2 (outliers) on
the hazard ratio (HR). Model 2 included
covariates from model 1 plus age, sex,
race, smoking status, renin-angiotensin
system (RAS) inhibitor use, and hyper-
tension. Model 3 included the covariates
in model 2 plus log2(eGFR) and log2(to-
tal urine protein concentration). Preva-
lent cardiovascular disease (CVD), HbA1c,
and LDL were excluded from all models
because they changed the HRs for com-
plement proteins ,5%. Diabetes dura-
tion was excluded from the models for
the outcomes of death and combined
ESRD/death for the same reason. The
Lunn-McNeil method was used to ex-
amine association between complement
proteins and ESRD while accounting for
the competing risk of death (16). The
nominal significance for all analyses
was a two-sided P value of,0.05. Anal-
yses were conducted using R, version
3.3.3 (R Core Team, 2017). The Cox
proportional hazards analyseswere con-
ducted using the R package survival,
version 2.41-3.
RESULTS
Participant Characteristics
The initial discovery study was conducted
using the urine samples from a cross-
sectional study of participants with
type 1 diabetes with or without protei-
nuric DKD (n = 61) (Supplementary Table
3). Subsequent targeted proteomics
studies used urine samples from partic-
ipants with type 2 diabetes and protei-
nuric DKD from the longitudinal Golden
State cohort (n = 141) (Table 1). The latter
participants had a mean age of 57 years,
were mostly male (57%) and Hispanic
(73%), and had a high prevalence of
current/past smoking (55%) with a me-
dian (IQR) diabetes duration of 14 (10,
19) years. At baseline, 94% had hyper-
tension and 35% CVD. A majority (82%)
were treated with RAS inhibitors. Me-
dian (IQR) SBP,DBP, andHbA1cwere155
(136, 176), 77 (70, 85), and 8.0% (7.1%,
10.0%), respectively. Median LDL and
HDL were 108 and 41 mg/dL, respec-
tively. Median eGFR and urineprotein-to-
creatinine ratio (PCR) were 54 mL/min/
1.73 m2 and 2.6 g/g, respectively. Com-
paredwith participants who neither died
nor developed ESRD in follow-up, those
whodidweremore likely tobemale (60%
vs. 54%) and white (19% vs. 11%), had a
higher prevalence of current/past smok-
ing (58% vs. 52%) and hypertension (96%
vs. 93%), had a lower prevalence of di-
agnosed CVD (31% vs. 39%) and RAS
inhibitor use (79% vs. 84%), and had a
highermedian SBP (159 vs. 152) and urine
PCR (3.6 vs. 2.0) and lower median eGFR
(44 vs. 62). Other than baseline eGFR and
proteinuria, none of the above differ-
ences between the groups reached sta-
tistical significance (Table 1). The two
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groups were similar in age, diabetes
duration, median HbA1c, LDL, HDL, and
DBP.
Untargeted Proteomics
Abundance of Complement Proteins in
Urine of People With Diabetes With or
Without DKD
Untargeted proteomics was used to
broadly compare the urine proteins in
people with type 1 diabetes and protei-
nuric DKD (n = 32) versus those without
DKD (control subjects; n = 29). Of the
469 proteins identified in a majority of
samples, 95 were higher in people with
DKD versus control subjects (P , 0.05).
The complement pathway was one of the
most highly represented pathways, with
nine proteins (complement component
3 [C3], 4, 5, 6, 7, 8a, 8g, 9, and complement
factor H) for which median abundance
per unit of urine protein was 1.8–7.8-
fold higher in people with DKD than
control subjects (P, 0.05) (Supplementary
Fig. 2).
Targeted Proteomics
Correlation Between Urine Complement
Proteins and eGFR or Proteinuria
The abundance of most complement
proteins per unit of total urine protein
(i.e., the fraction of total urine protein
that was composed of a given comple-
ment protein) was negatively correlated
with eGFR (Pearson r520.16 to20.49).
The exception was CD59, which was not
correlated with eGFR (r5 0.06) (Fig. 1A).
In contrast, the abundance of most
urine complement proteins (per unit
of total urine protein) was positively
correlated with total urine protein con-
centration, ranging from r 5 0.15 (clus-
terin) to r5 0.42 (C3 and C4). Only CD59
showed a strong negative correlation
with total urine protein (r520.53) (Fig.
1B).
Complement Proteins and the Risk for the
Combined Outcome of ESRD and/or Death
Of the 141 participants at risk, 67 de-
veloped ESRD and/or died during a
median (IQR) follow-up of 3.1 (1.7,
4.9) years for ESRD and 3.6 (2.1, 5.5)
years for all-cause death. Urine abun-
dance of each quantified complement
protein was included individually in time-
to-event analyses for the combined
ESRD/death outcome (Table 2). Four
complement proteins were associated
with ESRD/death after adjustment for
demographic and clinical parameters,
including baseline eGFR and protein-
uria (model 3). C4 and C8 were signifi-
cantly associated with ESRD/death only
in the fully adjusted model (model 3);
CD59 and FHR2 were significantly asso-
ciated with ESRD/death in all models.
Higher urine C4, C8, and CD59 were
associated with a lower risk (HRs [95%
CIs per doubling] 0.70 [0.53–0.91],
Table 1—Baseline characteristics of the participants from the Golden State cohort
Variable All ESRD or death Neither P value for trend
N 141 67 74
Age (years) 57 (8) 57 (7) 57 (8) 0.4
Male, N (%) 80 (57) 40 (60) 40 (54) 0.6
Race/ethnicity, N (%) 0.1
Hispanic 103 (73) 50 (75) 53 (72)
Caucasian 21 (15) 13 (19) 8 (11)
African American 12 (9) 4 (6) 8 (11)
Other 5 (4) 0 (0) 5 (6)
Smoking, N (%) 0.6
Current 21 (15) 9 (13) 12 (16)
Past 57 (40) 30 (45) 27 (36)
Never 63 (45) 28 (42) 35 (47)
Diabetes duration (years) 14 (10, 19) 14 (10, 20) 14 (10, 18) 0.6
Hypertension, N (%) 133 (94) 64 (96) 69 (93) 1.0
CVD, N (%) 50 (35) 21 (31) 29 (39) 0.4
RAS inhibitor use, N (%) 115 (82) 53 (79) 62 (84) 0.6
Aspirin use, N (%) 63 (45) 27 (40) 36 (49) 0.3
HMG-CoA reductase use, N (%) 89 (63) 42 (63) 47 (64) 0.9
SBP (mmHg) 155 (136, 176) 159 (138, 179) 152 (135, 173) 0.6
DBP (mmHg) 77 (70, 85) 77 (69, 85) 77 (71, 85) 0.5
BMI (kg/m2) 32 (9) 31 (8) 32 (9) 0.5
HbA1c (%) 8.0 (7.1, 10.0) 8.0 (6.9, 9.9) 8.0 (7.2, 10.0) 0.8
LDL (mg/dL) 108 (81, 136) 108 (85, 140) 109 (77, 129) 0.5
HDL (mg/dL) 41 (35, 49) 41 (35, 49) 41 (33, 49) 0.9
eGFR (mL/min/1.73 m2), mean 59 (23) 53 (25) 63 (21) 0.002
eGFR (mL/min/1.73 m2), median 54 (40, 75) 44 (33, 74) 62 (45, 76)
Urine protein (g/L), mean 3.1 (3.4) 3.8 (3.8) 2.5 (2.9) 0.03
Urine protein (g/L), median 1.8 (0.9, 4.3) 2.5 (0.9, 5.2) 1.5 (0.9, 3.1)
Urine PCR (g/g), mean 3.7 (3.5) 4.6 (4.2) 2.9 (2.5)
Urine PCR (g/g), median 2.6 (1.2, 5.3) 3.6 (1.4, 6.5) 2.0 (1.1, 3.6) 0.01
Data are displayed asmean (SD) andmedian (IQR) for continuous covariates andN (%) for categorical covariates where noted. To convert HDL and LDL
to mmol/L, multiply by 0.0259. HMG, hydroxymethylglutaryl.
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0.70 [0.51–0.95], and 0.60 [0.40–0.88],
respectively), whereas higher urine FHR2
was associated with a higher risk (HR
[95% CI] 1.77 [1.25–2.50]) for ESRD/death.
Replacing hypertension with SBP/DBP
(Supplementary Table 4), inclusion of
BMI (Supplementary Tables 5, 7, and 8),
or aspirin and hydroxymethylglutaryl-
CoA reductase inhibitor use (Supplemen-
tary Table 6) did not alter these findings
significantly. Furthermore, to limit model
overfitting, LDL, HbA1c, diabetes duration,
Figure 1—Correlations between the abundance of individual complement proteins and baseline eGFR (A) and total urine protein concentration (B).
Correlations are represented by the Pearson correlation coefficient (r). CFAB, complement factor B; CFAI, complement factor I; CLUS, clusterin.
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and prevalent CVD were excluded from
models because their inclusion changed
HR ,5% (Supplementary Tables 7 and
8).
Association of C4, C8, CD59, and FHR2 with
the Individual Outcomes of ESRD or Death
Of the 67 participants who sustained
ESRD and/or death, 39 developed ESRD
and 40 died, including 12 who developed
ESRD and subsequently died (Supplemen-
tary Table 9). C4, C8, CD59, and FHR2
were individually included in the time-
to-event analysis for each outcome of
ESRD or death (Table 3). In a fully ad-
justed model (model 3), higher urine
CD59 remained associated with lower
risk of ESRD (HR [95% CI] 0.50 [0.29–
0.87]), whereas FHR2 association with
ESRD lost significance after adjustment
for eGFR and proteinuria. Accounting
for the competing risk of death did
not alter these findings (Supplementary
Table 10). All four proteins were associ-
ated with death in the fully adjusted
model. Higher urine C4, C8, and CD59
were associated with a lower risk (HRs
[95% CI for doubling] 0.57 [0.41–0.79],
0.66 [0.44–0.97], and 0.56 [0.34–0.93],
respectively), whereas higher urine FHR2
was associated with a greater risk (1.61
[1.05–2.48]) of death.
CONCLUSIONS
In a cohort of predominantly Mexican
American participants with type 2 diabe-
tes, proteinuric DKD, and high rates
of ESRD and all-cause mortality, higher
urine CD59, an inhibitor of the comple-
ment pathway, was associated with lower
riskof ESRDandall-causemortality.Higher
urine C4 and C8 were associated with
lower, and higher FHR2 with higher, risk
of all-cause mortality. These associations
remained significant after adjustment
for demographic and clinical covariates,
including eGFR and proteinuria.
Several lines of evidence implicate
complement pathway activation in DKD
pathogenesis. Complement deposition
in the kidneys has been noted in DKD
animalmodels (17) andpeoplewithDKD
(18,19). Complement activation prod-
ucts were increased in urine of people
with DKD, but not those with minimal
change disease with comparable protein-
uria (20). Two more findings suggested
that urine complement might reflect
complement production and/or deposi-
tion in the kidneys in human DKD: tran-
scription of complement genes was
Table 2—Association of individual complement proteins with the combined outcome of ESRD and/or death
Protein
Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
C3 1.06 (0.79, 1.40) 0.71 1.07 (0.79, 1.45) 0.66 0.77 (0.57, 1.05) 0.10
C4 0.92 (0.71, 1.19) 0.52 0.88 (0.66, 1.16) 0.36 0.70 (0.53, 0.91) 0.008
C5 1.37 (1.03, 1.82) 0.03 1.47 (1.10, 1.95) 0.01 1.16 (0.85, 1.60) 0.35
C6 1.39 (1.04, 1.87) 0.03 1.45 (1.06, 1.98) 0.02 0.99 (0.69, 1.43) 0.97
C7 1.18 (0.89, 1.58) 0.25 1.21 (0.90, 1.61) 0.20 0.84 (0.59, 1.19) 0.33
C8A 0.96 (0.73, 1.27) 0.78 0.99 (0.74, 1.32) 0.92 0.70 (0.51, 0.95) 0.021
C9 1.19 (0.91, 1.55) 0.20 1.24 (0.93, 1.64) 0.14 0.97 (0.71, 1.32) 0.85
CLUS 1.45 (1.10, 1.91) 0.01 1.47 (1.11, 1.96) 0.01 1.24 (0.90, 1.69) 0.19
CD59 0.70 (0.53, 0.93) 0.01 0.64 (0.47, 0.87) 0.004 0.60 (0.40 0.88) 0.009
CFAB 1.29 (0.97, 1.71) 0.08 1.33 (0.99, 1.79) 0.06 0.93 (0.67, 1.31) 0.69
CFAI 1.52 (1.14, 2.02) ,0.01 1.59 (1.18, 2.14) ,0.01 1.23 (0.88, 1.73) 0.23
FHR2 2.11 (1.55, 2.86) ,0.00001 2.19 (1.61, 2.97) ,0.00001 1.77 (1.25, 2.50) 0.0014
Model 1was adjusted for experimental sample batch.Model 2was additionally adjusted for age, sex, race/ethnicity (Hispanic, non-Hispanic), smoking,
hypertension, and use of RAS inhibitors. Model 3 was further adjusted for log2(baseline eGFR) and log2(baseline urine protein concentration).
Statistically significant associations appear in boldface type. LDL, HbA1c, diabetes duration, and prevalent CVD were excluded from models
because their inclusion changed HR ,5%. CFAB, complement factor B; CFAI, complement factor I; CLUS, clusterin.
Table 3—Association of individual complement proteins C4, C8, CD59, and FHR2 with ESRD or death
Protein
Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
ESRD
C4 1.39 (0.86, 2.22) 0.18 1.25 (0.76, 2.06) 0.38 0.84 (0.55, 1.29) 0.43
C8A 1.25 (0.83, 1.89) 0.28 1.14 (0.73, 1.79) 0.56 0.68 (0.45, 1.06) 0.08
CD59 0.55 (0.37, 0.81) 0.002 0.56 (0.36, 0.87) 0.01 0.50 (0.29, 0.87) 0.01
FHR2 2.59 (1.69, 3.97) ,0.001 2.60 (1.67, 4.05) ,0.001 1.48 (0.90, 2.45) 0.13
Death
C4 0.70 (0.53, 0.92) 0.01 0.66 (0.48, 0.90) 0.009 0.57 (0.41, 0.79) 0.0009
C8A 0.74 (0.54, 1.00) 0.05 0.81 (0.58, 1.13) 0.21 0.66 (0.44, 0.97) 0.03
CD59 0.91 (0.65, 1.27) 0.57 0.73 (0.49, 1.08) 0.12 0.56 (0.34, 0.93) 0.02
FHR2 1.45 (1.03, 2.04) 0.03 1.61 (1.13, 2.28) 0.008 1.61 (1.05, 2.48) 0.03
Modelswere adjusted as described in Table 2, except thatmodels for ESRD also included diabetes duration. Statistically significant associations appear
in boldface type.
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increased in the tubulointerstitium of peo-
ple with DKD versus control subjects (21).
Furthermore, in people with proteinuric
DKD, urine C3 excretion correlated with
tubular C3 deposition (22) but not with
plasma C3 (20). In addition, inhibition of
complement activation in experimental
DKD reduced renal complement deposi-
tion, mesangial expansion, and glomeru-
lar injury, supporting a causal role for
complement activation in DKD progres-
sion (23,24).
The timing of any complement path-
way involvement in human DKD is un-
known. Elegant studies in experimental
models of proteinuric CKD outline a chain
of events beginning with activation of
the complement pathway by protein-
uria, leading to complement-mediated
release of proinflammatory cytokines
and growth factors from endothelial
and tubular epithelial cells. This then
promotes inflammatory cell infiltration
into the renal interstitium, leading to
tubulointerstitial inflammation and sub-
sequent fibrosis (25–28). Consistently,
human proximal tubular cells express
a membrane-bound C3-convertase ca-
pable of activating the alternative com-
plement pathway, culminating in insertion
of the membrane attack complex
(MAC). When exposed to human serum
proteins, these cells activate comple-
ment, leading to induction of inflam-
matory cytokines and cell lysis (25,29).
Furthermore, inhibiting complement ac-
tivation in proteinuric rodents reduces
tubulointerstitial injury without affecting
the degree of proteinuria (30–32). As
early as a decade ago (5), these obser-
vations led to the intriguing hypothesis
that complement activation may be a
potential mechanism by which protein-
uria leads to tubulointerstitial fibrosis
and progression of CKD. The current
study is the first report of an association
between urine complement proteins
and progression of proteinuric kidney dis-
ease in people with diabetes.
A key finding in this study is that in
people with proteinuric DKD, higher
urine CD59 is associated with a lower
ESRD risk. CD59, a major regulator of
the complement activity, is a trans-
membrane protein that binds to the
C5–8 complex and inhibits assembly
of C9 monomers into the terminal
complement complex, thus protecting
cells from complement-mediated injury
(33). This protective function has been
implicated in CD59-mediated attenua-
tion of kidney injury (34), as well as
atherosclerotic endothelial injury in ex-
perimental diabetes (35,36). Our findings
do not identify the source of urine CD59,
which may be renal (i.e., shed into urine
from apical membranes of renal cells) or
systemic (i.e., serum CD59 filtered through
the glomerulus). CD59 is expressedbymost
cells in the body, including those in the
kidneys. Its expression is increased in kid-
ney tubulointerstitium in people with
DKD (21), so renal expression may con-
tribute to the urine CD59 protein. If the
higher urine CD59 is a consequence of
higher renal CD59 expression, its asso-
ciation with a lower risk of ESRD may
reflect the CD59-mediated protection
from proteinuria-induced complement
activation and subsequent tubulointer-
stitial injury and fibrosis, eventually
leading to slower DKD progression and
longer time to ESRD. On the other hand,
CD59 is a small protein (14 kDa), and
higher urine CD59 may well represent
greater filtration of serum CD59. If so, its
association with lower ESRD risk may be
unrelated to complement activity in the
kidneys, but instead reflect a systemic
process that affects DKD progression.
In a further twist, hyperglycemia gly-
cates CD59 on a critical histidine residue
(His44) within its active site, rendering
CD59 incapable of inhibiting MAC assem-
bly (37). In kidneys of people with di-
abetes, glycatedCD59andMAC codeposit
in glomerular capillaries (34). Interest-
ingly, His44 is absent in CD59 from all
animal species sequenced to date and is
proposed to contribute to the unique
human susceptibility to DKD (37). The
CD59 glycation motif includes a lysine (K),
which, once glycated, cannot be cleaved
by trypsin. As a result, the pattern of
peptides generated from a trypsin di-
gest of glycated CD59 will be distinct from
that of unglycated CD59 (Supplementary
Fig. 3). The pattern of CD59 peptides
identified in urine, and used for this
study, together with the near-complete
correlation between them suggests that
all peptides identified in this study were
derived from unglycated CD59. Further-
more, the observed association between
this unglycated urine CD59 and lower
risks of ESRD and death in this study
fits well with prior reports showing that
the unglycated (but not the glycated)
CD59 can inhibit complement activation.
It would be additionally informative to
specifically quantify glycated CD59, in
parallel with the unglycated CD59, and
compare the association of each with
renal outcomes. Specific quantification
of glycated CD59 would require an im-
munoassay using an antibody specific to
glycated CD59 or development of a tar-
geted MS method to detect its specific
peptide pattern (Supplementary Fig. 3C).
Higher urine CD59 was also associated
with lower all-cause mortality. Lack of
adjudicated causes of death precluded
further dissection of this finding. How-
ever, CVD is a significant cause of death in
people with DKD, and CD59 deficiency
markedly exacerbates atherosclerosis in
rodents with diabetes, suggesting that
complement activation plays a role in
progression of atherosclerosis and that
complement inhibition by CD59 may
reduce complement-mediated endothe-
lial injury in CVD (36). As such, the
observed association between higher
urine CD59 and lower mortality may
reflect CD59-mediated protection of
endothelial cells from complement-
mediated injury in CVD. This hypothesis
would suggest that higher urine CD59
reflects higher serum CD59. In contrast,
given the strong association between
reduced eGFR and mortality, the asso-
ciation between urine CD59 and mor-
tality may be confounded by CD59
association with DKD progression and
ESRD. Adjustment for baseline eGFR
did not affect the association between
urine CD59 and mortality. However, de-
spite adjustment for baseline eGFR, a
greater rate of eGFR loss during the
follow-up in people with lower base-
line urine CD59 may still confound the
association between urine CD59 and
mortality.
In this study, higher urine C4 and C8
were associated with a lower risk and
higher urine FHR2 with a greater risk of
death. C4 is a nonenzymatic component
of theC3- andC5-convertases, generated
via the classical or lectin arms of the
complement cascade. C8 is a component
of the terminal complement complexes.
FHR2 belongs to the family of the com-
plement FHR proteins that block the
inhibition of the alternative pathway
by complement factor H. Taken at face
value, these findings suggest that greater
activation of the classical/lectin comple-
ment pathwaysmay be associatedwith
longer survival, whereas greater acti-
vation of the alternative pathway may be
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associated with shorter survival in this
population. However, the explanation is
likely much more complex. A majority of
deaths in the population with CKD/ESRD
are due to CVD and cancer (;62%
combined), with a much lower propor-
tion (;4%) from infectious causes (38).
Although complement activation is ben-
eficial against inflammatory and infec-
tious etiologies, it may promote cancer
growth and metastasis (39). Also, the role
of complement system in CVD is complex
and incompletely understood, with some
components inhibiting, and others pro-
moting, progression of atherosclerosis
(40). In addition, given the marked clin-
ical differences in CVD between the
CKD/ESRD and general population, it
is unclear how much of what is known
about the complement pathway in CVD
in the general population can be extrap-
olated to people with CKD/ESRD. As such,
deciphering the exact molecular mech-
anisms behind the association of C4, C8,
and FHR2 with all-cause mortality re-
quires further study. However, it is worth
noting that whereas higher complement
inhibitor CD59 is associated with lower
ESRD, activation of different arms of the
complement pathway may be associated
with both higher and lower risk of mor-
tality, perhaps dependent on the arm of
the pathway that is engaged. As such,
targeting the complement pathway for
therapeutic intervention requires a more
nuanced understanding of the effect of
each of its components on DKD progres-
sion, as well as mortality.
The strengths of this study are the
comprehensive quantification of urine
complement proteins using a robust
targeted MS method specifically devel-
oped for use in urine, the use of a
clinically relevant population with high
prevalence of DKD and its adverse out-
comes, use of the hard outcomes of ESRD
and death, and careful adjustment for
potential confounders. The study limita-
tions are themodest cohort size, absence
of parallel quantification of comple-
ment proteins in serum and kidney,
and lack of adjudicated causes of death.
Furthermore, given the strong associa-
tion between eGFR and both ESRD and
death, adjustment with eGFR (instead
of measured GFR) may leave residual
confounding. In addition, study partici-
pants were not evaluated for occult
urinary tract infections, which may in-
crease complement proteins in urine.
However, as we are not aware of data
suggesting that urinary tract infections
are more common in people who prog-
ress to ESRD or die, undetected urinary
tract infections are more likely to add to
noise than false-positive findings. Finally,
the findings of this study require valida-
tion in independent cohorts. Addition-
ally, it would be informative to include
control subjects without diabetes to
assess the impact of diabetes without
kidney disease on urine complement. Fur-
thermore, the above studies should be
repeated in timed urine collections to
determine if the urinary excretions of
these proteins are more strongly associ-
ated with the outcome than their abun-
dance in random samples. It is worth
noting that at least for urine albumin, its
quantity in spot urine samples is more
strongly predictive of renal events than
its excretion in timed urine collections.
In summary, in a group of largely His-
panic patients with type 2 diabetes and
proteinuric CKD, higher urine CD59 was
strongly associated with a substantially
lower risk of subsequent ESRD and death.
Three other complement proteins were
strongly associatedwithmortality. These
findings suggest a role for complement
pathway activation in DKD progression in
people with proteinuria.
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